Properties
What is it?
International Nonproprietary Name - fluticasone furoate Clinical-pharmacological group: Glucocorticoids → Glucocorticoid preparations for inhalation use Indications Asthma Flixotide has an anti-inflammatory effect on the lungs. It reduces the symptoms of asthma exacerbations in patients previously treated with a bronchodilator alone or in combination with other prophylactic therapy. Acute bronchial asthma requires regular medical examination, as a fatal outcome may occur. Patients with acute asthma experience persistent symptoms and frequent exacerbations, with limited physical ability and PEF values below 60% with 30% variability, which usually do not return to normal after taking a bronchodilator. Such patients require high-dose inhalation (see Dosage and Administration) or oral corticosteroid therapy. In case of sudden worsening of symptoms, it may be necessary to increase the dose of corticosteroids, which should be taken under medical supervision. • Adults Prophylactic management: Mild asthma (PEF value > 80% with variability < 20%): In patients requiring intermittent symptomatic bronchodilator therapy. Moderate asthma (PEF value 60-80% with variability > 30%): Patients requiring regular asthma treatment and patients with unstable or worsening asthma on existing prophylactic therapy or bronchodilator therapy alone. Severe asthma (PEF value < 60% based on variability > 30%): Patients with severe chronic asthma. After Flixotide inhalation, many patients dependent on systemic corticosteroids for adequate symptom control will be able to significantly reduce or discontinue oral corticosteroid use. • Children Every child requiring prophylactic asthma treatment, including uncontrolled patients or those on existing prophylactic therapy. Chronic Obstructive Pulmonary Disease (COPD) Flixotide is indicated for the management of COPD in combination with long-acting bronchodilators (e.g., long-acting beta-agonists (LABAs)). Dosage and Administration Patients should be informed about the prophylactic nature of inhaled Flixotide, so that they take it regularly even when they do not experience symptoms of the disease. Flixotide is intended for oral inhalation only. It is understood that each prescribed dose is delivered with at least two inhalations. In patients who have difficulty coordinating with a metered-dose inhaler, a spacer may be used with the Flixotide inhaler. Asthma Therapeutic effect is observed within 4-7 days, although it may sometimes develop within 24 hours in patients who have not previously received inhaled steroids. If a patient notices that relief of disease symptoms is less effective when using a short-acting bronchodilator, or if they require more inhalations than usual, medical attention is required. • Adults and children aged 16 years and older 100-1000 micrograms twice daily. Patients should be given the dose of inhaled Flixotide that corresponds to the severity of their disease: Mild asthma: 100-250 micrograms twice daily. Moderate asthma: 250-500 micrograms twice daily. Severe asthma: 500-1000 micrograms twice daily. The dose can then be adjusted until control is achieved or reduced to the minimum effective dose, according to individual response. Alternatively, the initial dose of fluticasone propionate can be divided into half the full daily dose of beclomethasone dipropionate or equivalent delivered by a metered-dose inhaler. • Children aged 4 years and older 50-200 micrograms twice daily.